These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 33750926)

  • 1. Genome editing using CRISPR/Cas9 to treat hereditary hematological disorders.
    Chen Y; Wen R; Yang Z; Chen Z
    Gene Ther; 2022 May; 29(5):207-216. PubMed ID: 33750926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome editing in human hematopoietic stem and progenitor cells via CRISPR-Cas9-mediated homology-independent targeted integration.
    Bloomer H; Smith RH; Hakami W; Larochelle A
    Mol Ther; 2021 Apr; 29(4):1611-1624. PubMed ID: 33309880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Versatile Tool for the Quantification of CRISPR/Cas9-Induced Genome Editing Events in Human Hematopoietic Cell Lines and Hematopoietic Stem/Progenitor Cells.
    Jayavaradhan R; Pillis DM; Malik P
    J Mol Biol; 2019 Jan; 431(1):102-110. PubMed ID: 29751014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
    Vermersch E; Jouve C; Hulot JS
    Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision genome editing in the CRISPR era.
    Salsman J; Dellaire G
    Biochem Cell Biol; 2017 Apr; 95(2):187-201. PubMed ID: 28177771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of genome editing technologies to the study and treatment of hematological disease.
    Pellagatti A; Dolatshad H; Yip BH; Valletta S; Boultwood J
    Adv Biol Regul; 2016 Jan; 60():122-134. PubMed ID: 26433620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
    Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
    Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas9 in genome editing: Its function and medical applications.
    Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM
    J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target binding and residence: a new determinant of DNA double-strand break repair pathway choice in CRISPR/Cas9 genome editing.
    Feng Y; Liu S; Chen R; Xie A
    J Zhejiang Univ Sci B; 2021 Jan; 22(1):73-86. PubMed ID: 33448189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR-Cas systems: ushering in the new genome editing era.
    Perez Rojo F; Nyman RKM; Johnson AAT; Navarro MP; Ryan MH; Erskine W; Kaur P
    Bioengineered; 2018; 9(1):214-221. PubMed ID: 29968520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Manipulation Using Fusion Guide RNAs for Cas9 and Cas12a.
    Shin HR; Kweon J; Kim Y
    Methods Mol Biol; 2021; 2162():185-193. PubMed ID: 32926383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas9 technology and its application in haematological disorders.
    Zhang H; McCarty N
    Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CRISPR/CAS9, the King of Genome Editing Tools].
    Bannikov AV; Lavrov AV
    Mol Biol (Mosk); 2017; 51(4):582-594. PubMed ID: 28900076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.
    Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A
    Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of genome editing through CRISPR-Cas9 engineering.
    Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
    Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases.
    Kim D; Luk K; Wolfe SA; Kim JS
    Annu Rev Biochem; 2019 Jun; 88():191-220. PubMed ID: 30883196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precise and Predictable CRISPR Chromosomal Rearrangements Reveal Principles of Cas9-Mediated Nucleotide Insertion.
    Shou J; Li J; Liu Y; Wu Q
    Mol Cell; 2018 Aug; 71(4):498-509.e4. PubMed ID: 30033371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editor's cut: DNA cleavage by CRISPR RNA-guided nucleases Cas9 and Cas12a.
    Swartjes T; Staals RHJ; van der Oost J
    Biochem Soc Trans; 2020 Feb; 48(1):207-219. PubMed ID: 31872209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas9 Genome Editing in Human Cell Lines with Donor Vector Made by Gibson Assembly.
    Sahoo N; Cuello V; Udawant S; Litif C; Mustard JA; Keniry M
    Methods Mol Biol; 2020; 2115():365-383. PubMed ID: 32006411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.